Objective-Drug-eluting coronary stents reduce restenosis rate and late lumen loss compared with bare-metal stents;
C oronary artery disease is the leading cause of mortality and morbidity in industrialized countries. 1 Coronary stents reduce the risk of periprocedural complications and restenosis when compared with angioplasty alone and have revolutionized interventional cardiology; however, in-stent restenosis remains a major clinical obstacle. 2 Drug-eluting stents (DES) have emerged as a highly promising approach to reduce in-stent restenosis. In fact, first-generation DES, such as sirolimus or paclitaxel-eluting stents, and second-generation DES, such as everolimus or zotarolimus-eluting stents, have substantially reduced angiographic and clinical restenosis across broad lesions and patient subsets. Next-generation DES include stents with bioresorbable polymers and bioresorbable stents. However, despite remarkable improvements in stent platform, polymer, and drug, the long-term results of DES usage have been blighted by the dual problems of instent restenosis and late stent thrombosis. DES unselectively inhibit migration and proliferation of both vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) and are associated with increased thrombocyte activation and aggregation compared with bare-metal stents. [3] [4] [5] In addition, immunosuppressive drugs, such as paclitaxel, decrease numbers and proliferative, migratory, adhesive, and tube formation capacities of endothelial progenitor cells, which play an important role in re-endothelialization. Delayed re-endothelialization and impaired endothelial function after DES have been suggested as a cause of increased rates of stent thrombosis compared with bare-metal stents. 6 The response to percutaneous coronary intervention (PCI)induced vascular injury is characterized by the sequence of inflammation, granulation, extracellular matrix synthesis, and VSMC proliferation and migration. In this process, VSMCs switch from a quiescent, contractile to a synthetic phenotype that proliferates and migrates in response to chemotactic factors, 7 leading to neointimal thickening and restenosis. 8 PCIinduced vascular injury causes release of growth factors, mainly platelet-derived growth factor (PDGF), which is produced by VSMCs, ECs, platelets, or macrophages and plays an important role in neointima formation. 9 In addition, previous studies have shown that glycolysis is enhanced in response to PDGF and changes in cell metabolism are both a hallmark and requirement for PDGF-induced cell proliferation. 10, 11 The peroxisome proliferator-activated receptor-delta (PPARδ, also called PPARβ), together with the other 2 siblings, PPARα and PPARγ, belongs to the nuclear receptor superfamily of ligand-activated transcription factors. These receptors form heterodimers with retinoid X receptors and bind to consensus response elements in the promoter region of their target genes. In the absence of ligand, PPARδretinoid X receptor heterodimers recruit corepressors, silencing transcription by the so-called active repression. Ligand binding induces a conformational change in PPAR-retinoid X receptor complexes, releasing corepressors in exchange for coactivators, which results in increased gene expression. 12 The naturally occurring ligands for PPARδ include polyunsaturated fatty acids, triglycerides, and prostacyclin. In addition, highly potent and selective synthetic PPARδ agonists such as GW501516 or GW0742 have been developed. PPARδ has been associated with regulation of inflammation, cell differentiation, proliferation, and apoptosis. 13 Moreover, PPARδ has beneficial effects on whole-body metabolism and improves several parameters of the metabolic syndrome in defined mouse models. 14 Preclinical and phase I/II trials suggest that PPARδ agonists increase high-density lipoprotein and decrease low-density lipoprotein cholesterol, reduce body fat and improve markers of inflammation in obese subjects. 15, 16 These findings prompted us to perform a proof-of-concept study to determine whether PPARδ ligands inhibit in-stent restenosis in a rabbit model of experimental atherosclerosis.
In the present study, we outline a promising role for PPARδ ligand-coated stents to address drawbacks of currently used DES. We demonstrate in vivo that PPARδ ligand-coated stents lead to a significant inhibition of strutassociated neointima when compared with vehicle-coated stents. This effect is mediated by a differential effect on VSMC and EC proliferation and migration, an attenuation of vascular inflammation, and an inhibition of thrombocyte activation and aggregation.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

PPARδ Ligand-Coated Stents Inhibit In-Stent Restenosis in Rabbit Atheromatous Arteries
Forty-six methylester conjugated PPARδ ligand (GW0742-Me)-or vehicle (ethanol)-coated stents (21 mm×3.5 mm; Translumina GmbH) were successfully implanted in the aorta of rabbits. A rabbit model of experimental atherosclerosis was used as described in the Method section of this article. To achieve a suitable release kinetic, we modified the synthetic PPARδ ligand GW0742 and produced methylester of GW0742 (GW0742-Me). Pharmacological release kinetic was determined ex vivo and in vivo (Results and Figures I and II in the online-only Data Supplement). Animals were randomized to either high-dose GW0742-Me-coated stents (445.4±61.2 μg), low-dose GW0742-Me-coated stents (151.2±15.4 μg), or vehicle-coated stents (ethanol). Time points for euthanasia were 14 and 42 days after stent deployment ( Figure III in the online-only Data Supplement). The rabbits appeared healthy with no signs of drug toxicity identified by weight loss, lethargy, or icterus. We collected blood samples for differential blood count, lipid profile, glucose, C-reactive protein, liver and kidney values at the time of aortic denudation, at the end of the atherogenic diet, before stent placement, and at day 14 and 42 after stent deployment. At all time points, analyzed laboratory values were not significantly different among the groups ( Table I in  the online-only Data Supplement) .
PPARδ ligand-coated stents lead to a significant inhibition of strut-associated neointimal area (29.57% inhibition with high-dose and 46.65% with low-dose-coated stents; P<0.05) compared with vehicle (ethanol)-coated stents ( Figure 1A and 1C ). In addition, cellular proliferation was significantly reduced both in the neointimal area (65.36% inhibition with high-dose and 79.35% with low-dose-coated stents; P<0.05) and in the underlying plaque area (53.6% inhibition with high-dose and 74.17% with low-dose-coated stents; P<0.05; Figure 1B Figure 1C ). Morphometric analysis of stented rabbit aortas revealed no difference between the groups with respect to external elastic lamina area, stent area, and atherosclerotic plaque area (data not shown). We next examined inflammatory gene expression in stented and unstented rabbit aortas. PPARδ ligand-coated stents significantly attenuated monocyte chemoattractant protein-1 (MCP-1; 41.66% inhibition with low dose; P<0.05) and interleukin-6 (IL-6) mRNA expression (47.3% inhibition with low dose; P<0.05) at 42 days after stent placement ( Figure 1D , left), whereas no effect on vascular cell adhesion molecule (VCAM) expression was observed (data not shown). In contrast, no difference in gene expression was observed in the arterial wall adjacent to the unstented segments ( Figure 1D , right).
PPARδ Activation Inhibits VSMC Proliferation and Migration
VSMC proliferation and migration stimulated by PDGF play a crucial role in the progression of atherosclerosis and the development of restenosis after coronary angioplasty. 17, 18 Previous reports suggest that different PPARδ ligands potentiate cell growth, whereas other studies suggest an attenuation of cell growth by PPARδ activation. [19] [20] [21] [22] To further analyze the effect of PPARδ activation on VSMC growth, the subtype-specific PPARδ agonist GW0742 was used in rat VSMCs (rVSMCs) resuming proliferation by PDGF-BB treatment after G 0 /G 1phase synchronization. GW0742 treatment (Figure 2A , left) inhibited rVSMC proliferation in a dose-dependent manner (40.59% inhibition at 10 μmol/L GW0742; P<0.05). To further characterize the role of PPARδ in cell proliferation, VSMCs were isolated from the aorta of PPARδ +/+ and PPARδ −/− mice. Electron microscopy analysis of PPARδ −/− VSMCs revealed no morphological differences in size and structure of cell nuclei, mitochondria, endoplasmic reticulum, Golgi complex, and cell-cell contact compared with PPARδ +/+ VSMCs (data not shown). Incubation of PPARδ wild-type mouse VSMCs with GW0742 attenuated cell proliferation (32.13% inhibition at 3 μmol/L GW0742; P<0.05), whereas no effect was observed in PPARδ-depleted cells (Figure 2A , right).
To analyze individual rVSMC chemotaxis, vehicletreated (DMSO) or GW0742-treated cells were allowed to migrate in the presence of a PDGF-BB gradient. Cell tracks were recorded by time-lapse microscopy and the Euclidean distance (straight line between starting and end point), the total distance and the directionality of cell migration were determined. As shown in Figure 2B , GW0742 treatment markedly reduced both the Euclidean distance (64.71% inhibition at 3 μmol/L GW0742; P<0.05) and the total distance (18.74% inhibition at 3 μmol/L GW0742; P<0.05) compared with vehicle-treated cells. Altogether, these data demonstrate that PPARδ ligands inhibit both proliferation and migration of VSMC through a receptordependent mechanism. Because VCMC proliferation and migration is associated with higher energy requirements, we examined the effect of GW0742 on both glycolytic flux (extracellular acidification rate) and mitochondrial oxygen consumption (oxygen consumption rate) using extracellular flux technology. rVSMCs were incubated with 10 μmol/L GW074 or vehicle for 24 . Peroxisome proliferator-activated receptor-delta (PPARδ) activation inhibits growth and platelet-derived growth factor (PDGF)-BB-directed migration of vascular smooth muscle cells (VSMCs). A, G 1 -arrested rat VSMC (rVSMC) and PPARδ −/− and PPARδ +/+ mouse VSMCs (mVSMCs) resumed growth by treatment with PDGF-BB (20 ng/mL). Cells were preincubated with GW0742 (GW) for 24 h as indicated before addition of mitogens. Cell proliferation of rVSMCs was determined using an ATP Assays (left). Proliferation of mVSMCs was assayed by counting the cells using a hematocymeter (right). B, The migration path of 30 representative rVSMC was plotted after normalizing the starting point to x=0 and y=0 (top). Red and black lines are cell tracks moving toward the PDGF-BB gradient or moving in other directions, respectively. Diagram shows analysis of euclidean distance and total distance of rVSMCs in the absence of the chemoattractant PDGF-BB (Con), with PDGF-BB alone and in the presence of PDGF-BB and GW0742. Data are presented as mean±SEM. *P<0.05 vs PDGF-stimulated cells, 1-way ANOVA with post hoc correction (Bonferroni).
hours and changes in glycolysis in response to both acute (data not shown) and chronic PDGF-BB (24 hours) treatment were analyzed. As depicted in Figure 3A (left), PDGF addition increased extracellular acidification rate (3.93-fold versus unstimulated cells; P<0.05), which was significantly reduced in GW0742 pretreated rVSMCs (24.32% inhibition; P<0.05).
Oligomycin was used to eliminate mitochondrial ATP production, thus inducing maximal glycolytic response. GW0742 ( Figure 3A , right) significantly attenuated oligomycininduced increase in glycolysis (24.42% inhibition; P<0.05). Next, the effect of GW0742 on mitochondrial oxygen consumption in both acute (data not shown) and chronic PDGF-BB-treated rVSMCs was analyzed. Treatment with GW0742 significantly decreased the maximal respiratory capacity without PDGF-BB (32.34% inhibition; P<0.05; Figure 3B , left). ATP-linked respiration was maintained during PDGF-BB treatment and compromised by GW0742 in the absence of PDGF-BB (ATP-linked respiration: basal minus oligomycin [proton leak] respiration; 23.03% inhibition; P<0.05; Figure 3C ). As GW0742 increased mitochondrial proton leak respiration (measured after oligomycin addition; Figure 3B , center), the reserve respiratory capacity was almost abolished on GW0742 treatment without PDGF-BB ( Figure 3B , right) to maintain ATP production. Taken together oxidative phosphorylation and glycolysis, PDGF enhances energy metabolism by increasing glycolysis and shifting ATP production toward glycolysis (Warburg-like effect). GW0742 attenuates glycolytic pathways and reduces the metabolic scope of mitochondria by decreasing spare respiratory capacity. The adenosine 5′-monophosphate-activated protein kinase (AMPK) is a key metabolic sensor that responds to cellular energy deprivation by inhibiting ATP-depleting processes and ATP-promoting processes that increase ATP synthesis within the cell. 23 This prompted us to investigate whether PPARδ ligands induce AMPK phosphorylation. As shown in Figure 3D , stimulation of rVSMCs with GW0742 dose-dependently induced AMPK phosphorylation at threonine 172.
To further characterize the role of PPARδ in energy metabolism, rVSMCs were stimulated with GW0742 and metabolic gene regulation was analyzed. As shown in Figure 3E , PPARδ ligand treatment induces expression of pyruvate dehydrogenase kinase isozyme 4 mRNA (7.74-fold versus unstimulated cells; P<0.05), whereas the expression of key regulators of fatty acid transport (Fabp3) and oxidation (Cpt1b, SCD1, SCD2, Acsl1, and Acot1) were unaltered by GW0742 treatment (data not shown). In contrast, the expression of GLUT1, the predominant glucose transporter protein in VSMCs, 24 was markedly downregulated (36.0% inhibition; P<0.05).
PPARδ Activation Suppresses Cytokine-Induced Inflammatory Gene Expression in VSMCs
Because inflammation is a key component in in-stent restenotic lesion formation, 25 we analyzed the function of PPARδ in VSMCs in this process. To determine the effect of synthetic PPARδ ligands on cytokine-induced inflammatory gene expression, quiescent rVSMCs, pretreated with GW0742 for 24 hours, were stimulated with tumor necrosis factor-α (10 ng/mL) for additional 8 hours. As depicted in Figure 4A , PPARδ ligand inhibits tumor necrosis factor-α-stimulated IL-6, MCP-1, and VCAM mRNA expression in a dosedependent manner (at 10 μmol/L GW0742 64.69% inhibition of IL-6; 69.0% inhibition of MCP-1; 75.83% inhibition of VCAM versus tumor necrosis factor-α alone; P<0.05). We next used mouse VSMCs isolated from the aorta of PPARδ +/+ and PPARδ −/− mice to further address whether the observed inhibitory effect is mediated by PPARδ. The inhibitory effect of GW0742 ( Figure 4B ) on inflammatory gene expression in PPARδ wild-type mouse VSMCs was completely abolished in PPARδ knockout cells, demonstrating that PPARδ ligands repress IL-6, MCP-1, and VCAM through a receptor-dependent mechanism.
Previous studies indicate that, in the absence of a specific ligand, PPARδ binds the transcriptional repressor B-cell lymphoma 6 (Bcl-6) and PPARδ ligand binding causes a dissociation of Bcl-6 from PPARδ. 26 This interaction prompted us to address the role of Bcl-6 in regulating inflammatory gene expression in VSMCs. Therefore, we transiently transfected rVSMCs with a Bcl-6 overexpression vector. As shown in Figure 4C , Bcl-6 overexpression resulted in a significant inhibition of IL-6, MCP-1, and VCAM mRNA expression in rVSMCs. We next performed chromatin immunoprecipitation assays to determine whether PPARδ ligand treatment induces Bcl-6 binding to the endogenous IL-6, MCP-1, and VCAM promoter. Using primer pairs that cover regions in the proximal IL-6, MCP-1, or VCAM promoter, we demonstrate that PPARδ ligand treatment induces Bcl-6 binding to the corresponding inflammatory gene promoter sequences ( Figure 4D ). Together, these data show that PPARδ ligand treatment of VSMCs induces a dissociation of Bcl-6 from PPARδ and subsequent binding to specific regions within inflammatory gene promoters, thus inhibiting corresponding gene expression.
PPARδ Ligand Inhibits Thrombocyte Activation and Aggregation
Platelets not only are essential to hemostasis and thrombosis but also activate immune cells and mediate inflammation. 27 Although platelets contain no nucleus, many nuclear receptors were found to be expressed in platelets including all 3 PPAR subtypes and their binding partner retinoid X receptor. [28] [29] [30] Thus, we investigated the effect of PPARδ ligand on thrombocyte activation and aggregation in vitro. Consistent with the previous observation, 29 PPARδ was expressed in human platelets ( Figure 5A ). PPARδ ligand GW0742 dose-dependently inhibited ristocetin (0.75 μg/ mL)-induced maximal aggregation (56.13% inhibition at 100 μmol/L GW0742) and maximal aggregation velocity (55.77% inhibition at 100 μmol/L GW0742) of human platelets in vitro. However, GW0742 did not affect collagen-induced platelet aggregation (data not shown).
We next performed activation assays in platelets isolated from PPARδ −/− and age-matched controls. Notably, GW0742 significantly attenuated ADP-induced thrombocyte aggregation in PPARδ +/+ platelets (28.38% inhibition at 10 μmol/L GW0742), whereas no effect was observed in PPARδdepleted platelets ( Figure 5B ). Interestingly, ADP-induced thrombocyte aggregation was attenuated in PPARδ knockout compared with wild-type platelets.
To investigate the effect of PPARδ ligand-coated stents on thrombocyte activation and aggregation, GW0742-Me-and vehicle (ethanol)-coated stents were implanted in a low-grade thrombogenic closed-loop system and perfused with human platelet-rich plasma at shear rates far below the threshold value at which activation of platelets occurs. 31 Number of circulating platelets, glycoprotein (GP) Ib and IIb/IIIa expression and activation (PAC-1 [platelet-associated complement-1] binding), P-selectin (CD62) and CD63 expression were evaluated before and after 1, 11, and 21 circulations ( Figure 5D ). The number of single circulating platelets was significantly reduced by 15.2% after 21 circulations (P<0.05) of vehicle-coated stents, whereas no effect on platelet number was observed with PPARδ ligandcoated stents. In contrast to GW0742-Me-coated stents, the platelet reactivity index increased after perfusion of vehiclecoated stents by 12.3% (P<0.05), indicating that the decrease in circulating platelets is attributable to an increased adherence to the stent, rather than to aggregate formation. In accordance, platelet thrombi were observed between struts of vehicle-coated stents ( Figure 5C ), but not between struts of GW0742-Mecoated stents. As determined by flow cytometry, the density of GP Ib receptor per platelet was significantly reduced in the vehicle-coated stent group (-12.4%; P<0.05) but remained unchanged in the GW0742-Me-coated stent group. After 21 circulations, the density of GP IIb/IIIa and the number of PAC-1-positive platelets were increased with vehicle-coated stents by 13% and 6.9% (both P<0.05), indicating thrombocyte activation. In contrast, in GW0742-Me-coated stents, no changes in the expression of GP IIb/IIIa and PAC-1 on the platelet surface was observed. Finally, the concentration of the thrombin-antithrombin III complex, indicating an activation of the coagulation system, was significantly increased in the vehicle-coated group after 21 circulations (+37.9%; P<0.05), but remained unchanged in the GW0742-Me-coated group (data not shown). The fraction of CD62-and CD63-positive platelets did not differ among the groups (data not shown).
PPARδ Activation Induces Human Umbilical Vein Endothelial Cell Proliferation and Migration
PPARδ regulates EC proliferation, angiogenesis, and EC survival. 32 However, the role of PPARδ in ECs is controversial, as both an inhibition and induction of EC proliferation and angiogenesis on PPARδ ligand stimulation has been reported. 33, 34 Treatment of primary human umbilical vein endothelial cells (HUVECs) with PPARδ ligand (1 μmol/L GW0742) increased EC number (1.17-fold versus unstimulated control), whereas both sirolimus and tacrolimus attenuated HUVEC proliferation compared with untreated control cells (24.09% inhibition at 10 nmol/L sirolimus (36.42% inhibition at 20 μmol/L tacrolimus; P<0.05; Figure 6A ). To analyze chemotaxis of HUVECs, vehicle-treated (DMSO) or GW0742-treated cells were allowed to migrate in the presence of a VEGF (vascular endothelial growth factor) gradient. Cell tracks were recorded by time-lapse microscopy, and the Euclidean distance and total distance were analyzed. GW0742 treatment significantly enhanced the chemotaxis of HUVECs compared with vehicle-treated cells ( Figure 6B) . To analyze the effect of PPARδ ligands on cell attachment and spreading dynamics, we used the xCELLigence System. Figure 6C , GW0742 increased adhesion and spreading of HUVECs when compared with untreated cells.
As shown in
Vascular Injury Induces PPARδ Expression in Rat Carotid Arteries and Human Coronary Arteries
As shown in Figure 7A , PPARδ expression was upregulated in the neointima 14 days after carotid artery balloon injury in 3-month-old Sprague-Dawley rats. Similar to the rat carotid artery injury model, we observed increased PPARδ expression in human coronary arteries after PCI. At 2 weeks after stenting, the stent struts were covered by neointimal tissue, composed mainly of VSMCs with infiltrating macrophages. At this time point, PPARδ expression was highly upregulated in the neointima in both macrophages and VSMCs compared with the underlying atherosclerotic lesion. In contrast, 2 days after PCI without stent placement and 3 years after stenting, only weak PPARδ expression was detected in the atherosclerotic lesions and neointimal areas ( Figure 7B and 7C) . 
Discussion
We demonstrate that PPARδ ligand-coated stents strongly reduce neointima formation in a rabbit model of experimental atherosclerosis. We attribute this effect to an inhibition of VSMC proliferation, reduced migration, and downregulated inflammatory gene expression. Furthermore, we observed an attenuation of thrombocyte activation and aggregation, as well as an induction of EC adhesion, proliferation, and chemotaxis according to the mechanistic schema that we suggest ( Figure VI in the online-only Data Supplement).
The neointima in our rabbit model of experimental atherosclerosis closely mimicked the angioplasty processes in humans, as stents are implanted in preformed atherosclerotic lesions. Aside from stent design, the rate and duration of drug release from the stent and the accumulation of drug in the vessel wall plays an important role in arterial healing. 35 As high-performance liquid chromatography-based analysis depicted an ≈100% GW0742 release from coated stents in vitro within 15 minutes, we modified the solubility of GW074 by methylester conjugation. Using GW0742-Me-coated stents, we achieved a sustained drug release and intramural deposition both in vitro and in vivo. We show that GW0742-Me-coated stents markedly reduce neointima formation and luminal narrowing both 14 and 42 days after stent placement. This result was accompanied by a significant reduction in cell proliferation both in the neointima and in the underlying atherosclerotic lesion. In addition, stent coating with GW0742-Me strongly attenuates inflammatory gene expression in the underlying vessel wall. However, a limitation of our study is the lack of a comparison with a commercially available DES. We also analyzed thrombocyte deposition 14 days after stent placement (data not shown). However, thrombocyte deposition to uncovered stent struts 14 days after placement of vehicle or GW0742-Me-coated stents was rare, as adhesion of platelets to the endoluminal side of the stents occurs early after stent deployment. 36 Interestingly, whereas our in vitro experiments clearly show a dose-dependent and PPARδ receptor-mediated effect of PPARδ ligands, in vivo the attenuation of neointima formation was more effective with low-dose GW0742-Me-coated stents. We cannot exclude that the inverse dose-dependent effect of PPARδ ligand (GW0742-Me)-coated stents on neointima formation comes from PPARδ receptor-independent modes of action such as activation or inhibition of other nuclear receptors. Thus Nandhikonda et al 37 previously reported that GW0742 exhibits characteristics of a pan nuclear receptor antagonist at high concentrations. In addition, differences in neointima formation could represent local toxicity caused by high-dose GW0742-Me-coated stents. Moreover, in our study, stents were not examined beyond 42 days, thus precluding assessment of possibly different longterm effect of high-dose and low-dose GW0742-Me-coated stents on neointima formation. In-stent restenosis and bypass graft failure are characterized by excessive VSMC proliferation, leading to luminal narrowing. However, data on the role of PPARδ in modulating cell proliferation are controversial, as both increased and decreased cell proliferation rates by synthetic PPARδ ligands have been reported previously. 19, 38 Whereas Lim et al 19 reported that adenovirus-mediated overexpression of PPARδ suppresses PDGF-induced VSMC proliferation, Zhang et al 39 found that overexpression of PPARδ in VSMCs increases postconfluent cell proliferation. In addition, Lim et al used L-165041, the first synthetic compound that not only activates PPARδ, but also triggers PPARγ activation at high doses. 40 As the role of the nuclear receptor PPARδ in mediating the opposite growth modulatory effects of PPARδ ligands on various cell types has not clearly been defined, we analyzed the effect of GW0742 on both normal and PPARδdepleted VSMCs. Our data indicate that the PPARδ ligand GW0742 inhibits proliferation and migration of VSMCs in vitro in a PPARδ receptor-dependent manner. Given the increased energy requirements for cell proliferation and chemotaxis, we examined the effect of the synthetic PPARδ agonist GW0742 on glycolysis and mitochondrial respiration using extracellular flux analysis. Consistent with previously published studies, 11 our data demonstrate that PDGF stimulation enhances glycolysis in VSMCs. We found that under both acute and chronic treatment conditions, GW0742 inhibits PDGF-induced augmentation of glycolysis. In addition, GW0742 treatment significantly attenuates the maximal respiratory capacity and the reserve respiratory capacity and increases the mitochondrial proton leak respiration. The observed effect of GW0742 on PDGF-induced glycolysis and mitochondrial respiration impairs the ability of VSMCs to provide the increased energy demands required for growth factor-stimulated proliferation and migration of VSMCs. PPARδ activation is known to regulate many genes involved in fatty acid and glucose utilization. 41 However, data about the effect of PPARδ ligands on glucose metabolism are controversial, as both impaired and increased glucose utilization has been reported. 42, 43 Our data show that GW0742 treatment strongly induces pyruvate dehydrogenase kinase isozyme 4 in VSMCs. Pyruvate dehydrogenase kinase isozyme 4 phosphorylates and inactivates pyruvate dehydrogenase, which inhibits the utilization of pyruvate for acetyl-CoA synthesis and thus blocks glucose oxidation. In addition, we found that the expression of GLUT1, the predominant isoform of glucose transporter proteins in VSMCs, 24 was significantly reduced in response to GW0742 treatment.
The signaling pathways that link changes in VSMC energy metabolism and function are poorly understood. Recently, AMPK emerged as important regulator of metabolic processes and VSMC migration and proliferation. 44 Our data demonstrate that GW0742 treatment of VSMCs induces AMPK phosphorylation of the catalytic α domain at threonine 172. AMPK is a key metabolic sensor that is phosphorylated in response to cellular energy deprivation and stress 45 and acts to restore energy homeostasis by switching off ATPconsuming processes and switching on catabolic pathways that generate ATP. However, the relationship of AMPK in PPARδ-mediated inhibition of cell proliferation is complex.
As AMPK activation in skeletal muscle was previously found to be PPARδ independent, 43 the observed induction of AMPK phosphorylation in VSMCs after GW0742 treatment is likely either because of the change in cellular energy metabolism or mediated directly via heme oxygenase-1 ( Figure IV in the online-only Data Supplement). In accordance, Kim et al 46 recently observed that heme oxygenase-1 induces activation of AMPK in VSMCs.
The inflammatory response of VSMCs plays an important role in neointima formation after PCI. Our data demonstrate that PPARδ ligands inhibit tumor necrosis factor-α-induced expression of IL-6, MCP-1, and VCAM by inducing Bcl-6 binding to the corresponding inflammatory gene promoter sequence. Early studies indicate that PPARγ is not required for the anti-inflammatory effect of its ligands. 47 However, by use of primary cultures of VSMCs from wild-type and PPARδ −/− mice, we demonstrate that PPARδ ligands inhibit inflammatory gene expression in a receptor-dependent manner. Taken together, GW0742 affects crucial biological VSMC functions, including proliferation and gene expression, which is compatible with beneficial outcome in experimental restenosis.
The interaction of platelets with the surface of DES plays an important role in both in-stent restenosis and stent thrombosis. Thrombocyte adhesion and aggregation is mediated by a variety of surface glycoproteins such as GP IIb/IIIa, GP VI, or the GP Ib-IX-V complex. 48 On Upon activation, GP IIb/IIIa undergoes a conformational change, and additional intraplatelet pools of GP IIb/IIIa are released that increase the surface density. In addition, von Willebrand factor plays an important role in platelet adhesion at the site of endothelial injury, as it mediates platelet-subendothelium interaction by linking the platelet receptor GP Ib-IX-X to the extracellular matrix. 49 To date, no stent coating with an antithrombotic effect has been developed. Strikingly, we found that GW0742-Me coating effectively prevents human thrombocyte deposition to the stents surface and thrombocyte activation in vitro. As determined by flow cytometry, both platelet surface receptor GP IIb/IIIa surface density and activation (PAC-1 binding) increased after perfusion of vehicle-coated stents, whereas no change was observed with GW0742-Me-coated stents. In addition, perfusion of vehicle-coated stents increased the thrombin-antithrombin III values, indicating the thrombin generation of adhering activated platelets, which leads to the activation of the plasmatic coagulation. The density of GP Ib receptor per platelet was significantly reduced in the vehiclecoated stent group, which reflects a higher activation in the closed-loop system. 50 Furthermore, PPARδ ligand GW0742 dose-dependently inhibited ristocetin-induced human thrombocyte aggregation in vitro, whereas no effect was observed on collagen-induced platelet aggregation at a concentration of 5 μg/mL. Both ristocetin and collagen induce platelet aggregation via common pathways such as activation of phospholipase C (PLC). However, as ristocetin forms a complex with von Willebrand factor that facilitates binding to the GP Ib-IX-V complex, the specific inhibition of ristocetin-induced platelet aggregation by GW0742 could be attributed to an inhibition or dissociation of the von Willebrand factor-GP Ib-IX-V complex.
In contrast to our observation, Ali et al 29 reported in 2006 that PPARδ ligands (L-165041; GW0742) inhibit human platelet activation induced by various stimuli such as collagen, thrombin, and ADP. However, in this study, measurements were performed in whole-blood and higher concentrations of both the agonists and the PPARδ ligand GW0742 were used, which might explain the different results. Thus, it was recently reported that nitrite inhibits P-selectin expression on the platelet membrane and GP IIb/IIIa activation in response to ADP, collagen, and thrombin stimulation in the presence of erythrocytes, and this inhibition was promoted by increasing hematocrit and deoxygenation of erythrocytes (what takes place during storage), suggesting that NO produced by the reaction of nitrite with deoxyhemoglobin was responsible for this inhibitory effect. 51 Whereas a previous study reported that the ability of PPARδ agonist GW501516 to inhibit ADPinduced platelet aggregation was similar in PPARδ −/− and PPARδ +/+ mouse thrombocytes, 52 our data demonstrate that GW0742 mediated inhibition of thrombocyte aggregation is receptor dependent, as the effect was abolished in PPARδ −/− platelets. In summary, differences between previous reports and our results might be attributed to a variety of different factors, including different specificities of PPARδ agonists for other PPAR isoforms, different potencies of various PPARδ compounds, different in vitro conditions (wholeblood versus platelet-rich plasma), or use of different PPARδ knockout mouse models.
Recent studies indicate that a rapid re-endothelialization of the stented area is associated with a lower risk of inflammation and subsequent thrombus formation. 53 A major concern with currently used DES is impaired re-endothelialization because of the drug. 54 Endothelial regrowth after stenting depends on both migration from intact neighboring coronary segments, and attraction and adhesion of circulating endothelial progenitor cells. Previous studies have shown that sirolimus and paclitaxel inhibit proliferation and migration of ECs in vitro, 55, 56 thereby potentially impairing re-endothelialization. Data on the role of PPARδ in ECs are controversial, as both proproliferative and antiproliferative effects have been reported. 33, 34 Our data demonstrate that GW0742 induces proliferation and VEGF-induced migration of cultured ECs. In addition, adhesion and spreading, essential processes for EC migration, were accelerated in GW0742-treated ECs. However, in our rabbit model of experimental atherosclerosis, no difference in re-endothelialization was evident with the use of GW0742coated stents compared with vehicle-coated stents as endothelial regrowth was already almost complete at day 14 ( Figure V in the online-only Data Supplement). Although animal models of stenting probably predict human responses as the stages of healing are remarkably similar, previous studies have shown that endothelial regrowth is significantly more rapid in the rabbit model than in the humans, where re-endothelialization is only complete by 3 to 4 months after bare-metal stent implantation or may even not fully endothelialize several years after implantation. 6, 57 We did not clearly define the underlying mechanism responsible for the contrary effect of PPARδ activation by synthetic ligands on proliferation/migration of VSMCs and ECs. However, we can speculate that the different effect of PPARδ on proliferation of VSMCs and EC comes from cell-type-specific expression levels of coactivators and corepressors, differences in post-translational modifications and proteosomal degradation of PPARδ.
In conclusion, our data demonstrate that PPARδ ligandcoated stents lead to significant inhibition of in-stent neointima formation compared with vehicle-coated stents. We attribute this effect to an inhibition of VSMC proliferation and inflammatory gene expression and potentially an inhibition of thrombocyte activation and a proproliferative and promigratory effect on ECs. Thus, PPARδ ligand-coated stents might be a promising strategy to address the problems of in-stent restenosis and late-stent thrombosis. Further preclinical studies and clinical trials are needed to test this hypothesis.
